Supply model, page-9

I know China can be quite tricky, since usually at least one of the trial sites has to be in China for results to be accepted.

But, Zolpimist is probably going to be easier to approve due to the base medicines wide availability.
I am assuming since its a reformulation of a well known drug already available there, that an existing GMP from our manufaturer, the existing FDA approval and further evidence of bio-equivalence would be all that is required of Eddingpharma.

Be interesting to know where they are at with things.